Reports Q1 revenue $11.83B, up 11% in cc, up 10% in U.S. dollars. Commenting on Q1 results, Vas Narasimhan, CEO of Novartis, said: “Novartis continued our strong momentum with both sales growth and core margin expansion in Q1. Our performance was broad-based, across all key growth brands and geographies, allowing us to raise guidance for the full year 2024. We continued to advance our pipeline in Q1, with submission-enabling data for Scemblix first-line, Pluvicto pre-taxane and remibrutinib in CSU. The momentum in our business and pipeline gives us continued confidence in our mid- and long-term growth outlook.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- NVS Earnings: Novartis Beats Q1 Estimates, Raises Outlook
- VGK vs. EZU: Which Is the Better European Stock ETF?
- Novartis announces data from the ALITHIOS study of Kesimpta
- Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
- MorphoSys board recommends shareholders accept Novartis offer